The first BsAb approved for cancer treatment was catumaxomab, which activates endogenous T cells by connecting CD3 with epithelial cell adhesion molecule (EpCAM) on cancer cells, indicating for malignant ascites therapy 48. The gene discussed is EPCAM; the disease is cancer.